RxDoctor Payments Data

Jenny Minton

Nurse Practitioner · Anniston, ALNPI 1619590098

Payments from drug & device makers

$6,223in general payments, 2019–2025

Across 299 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$693
  • Pfizer$510
  • AstraZeneca$463
  • Merck$412
  • Johnson & Johnson$315
  • Takeda Pharmaceuticals U.S.A., Inc.$300
  • plus $4K from 49 others

What the payments were for

  • Food & beverage$5,90295%
  • Education$3225%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,223 in reported general payments places this provider in the 90th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$186,171
Medicare patients
195
Services billed
5,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5018$19,732
EliquisApixaban12$6,780
Exemestane26$5,374
Letrozole58$1,550
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen25$706
Tamoxifen Citrate16$679
Hydroxyurea26$602
Dexamethasone31$545
Potassium Chloride29$381
Ondansetron OdtOndansetron19$283
Prochlorperazine Maleate14$208
Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12)21$193
Sertraline Hcl13$189
Levothyroxine Sodium18$164
Gabapentin16$162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$510$6,78012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Anniston

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →